WARRINGTON, Pa., Oct. 15, 2010 (GLOBE NEWSWIRE) -- Discovery Laboratories, Inc. (Nasdaq:DSCO) today announces that the Phase 2a clinical study of aerosolized KL4 surfactant (lucinactant) in patients with cystic fibrosis (CF) has completed and the results from the study will be presented at the upcoming North American Cystic Fibrosis Conference (NACFC; October 21-23, 2010). The trial was conducted as an investigator-initiated study under the direction of Dr. Scott H. Donaldson at The University of North Carolina (UNC) with support from PARI Pharma, and was funded by Cystic Fibrosis Foundation Therapeutics, Inc., a nonprofit affiliate of the Cystic Fibrosis Foundation. Preliminary observations from this trial include the determination that delivery of aerosolized KL4 surfactant to CF patients is feasible and that aerosolized KL4 surfactant was generally safe and well tolerated in this trial. Additionally, no serious adverse events (SAEs) were reported following treatment with aerosolized KL4 surfactant. The trial results, including assessment of exploratory effectiveness of aerosolized KL4 surfactant in CF patients, are embargoed until the NACFC presentation.
